Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Maridebart cafraglutide (known as MariTide) is a long-acting peptide-antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide receptor antagonism and that is intended for the treatment of obesity. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial that included 11 groups as two cohorts. Participants with obesity (obesity cohort) were randomly assigned in a 3:3:3:2:2:2:3 ratio to receive maridebart cafraglutide subcutaneously at a dose of 140, 280, or 420 mg every 4 weeks without dose escalation; 420 mg every 8 weeks without dose escalation; 420 mg every 4 weeks with 4-week dose escalation; 420 mg every 4 weeks with 12-week dose escalation; or placebo. Participants with obesity with type 2 diabetes (obesity-diabetes cohort) were randomly assigned in a 1:1:1:1 ratio to receive maridebart cafraglutide at a dose of 140, 280, or 420 mg every 4 weeks (all without dose escalation) or placebo. The primary end point was the percent change in body weight from baseline to week 52. RESULTS: We enrolled 592 participants. In the obesity cohort (465 participants; female sex, 63%; mean age, 47.9 years; mean body-mass index [BMI, the weight in kilograms divided by the square of the height in meters], 37.9), the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand (intention-to-treat approach) ranged from -12.3% (95% confidence interval [CI], -15.0 to -9.7) to -16.2% (95% CI, -18.9 to -13.5) with maridebart cafraglutide, as compared with -2.5% (95% CI, -4.2 to -0.7) with placebo. In the obesity-diabetes cohort (127 participants; female sex, 42%; mean age, 55.1 years; mean BMI, 36.5), the mean percent change in body weight from baseline to week 52 on the basis of the treatment policy estimand ranged from -8.4% (95% CI, -11.0 to -5.7) to -12.3% (95% CI, -15.3 to -9.2) with maridebart cafraglutide, as compared with -1.7% (95% CI, -2.9 to -0.6) with placebo. The mean change in the glycated hemoglobin level on the basis of the treatment policy estimand in this cohort was -1.2 to -1.6 percentage points in the maridebart cafraglutide groups and 0.1 percentage points in the placebo group. Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose. No unexpected safety signals emerged. CONCLUSIONS: In this phase 2 trial, once-monthly maridebart cafraglutide resulted in substantial weight reduction in participants with obesity with or without type 2 diabetes. (Funded by Amgen; ClinicalTrials.gov number, NCT05669599.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase 2 trial of people with obesity (with or without type 2 diabetes) who received maridebart cafraglutide every 4 weeks for 52 weeks, bodyweight was reduced by up to 16•2% (95% CI 13•5-18•9) compared with a 1•7% reduction with placebo.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [129]
In the citing paper
“Furthermore, HbA 1c was reduced in the cohort with type 2 diabetes by up to 1•5% (1•0-1•9) versus an increase of 0•1% with placebo.129”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [129]
In the citing paper
“Tolerability may also be improved through patient education, gradual dose escalation, and proactive side-effect management, while newer formulations, including longer-acting and oral agents, may reduce treatment burden and improve adherence.78,106,107”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [106]
In the citing paper
“Tolerability may also be improved through patient education, gradual dose escalation, and proactive side-effect management, while newer formulations, including longer-acting and oral agents, may reduce treatment burden and improve adherence.78,106,107”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [106]
In the citing paper
“Similarly, maridebart carfraglutide, known as MariTide, a long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism, achieved 12.3–16.2% WL after 52 weeks in obese participants with slightly lower reductions in individuals with T2DM [146].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [146]
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationAssociation analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Cited by
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 83
“The primary outcome assessed in week 104 is the change in the Clinical Dementia Rating Sum of Boxes score.”
Brain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025) · Journal of Obesity · doi:10.1155/jobe/9919810 · Cited by 24
“Te obesity–diabetes cohort mean percent change in body weight ranged from − 8.46% (95% CI, − 11.0 to − 5.7) to − 12.3% (95% CI, − 15.3 to − 9.2) [77, 78].”
InfluentialPharmacological therapies for type 2 diabetes: future approaches
Bailey, C. J. (2025) · Diabetologia · doi:10.1007/s00125-025-06581-6 · Cited by 28
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“Similarly, maridebart carfraglutide, known as MariTide, a long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism, achieved 12.3–16.2% WL after 52 weeks in obese participants with slightly lower reductions in individuals with T2DM [146].”
InfluentialOral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 17
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
The evolving landscape of pharmacogenomics: Current achievements and future directions
Lauschke, V. M., & Ingelman‐Sundberg, M. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100122 · Cited by 16
Lempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“In phase 2 trials, maridebart cafraglutide achieved weight reductions of up to 16.2% at 52 weeks in adults with obesity without T2DM (treatment policy estimand), and up to 19.9% based on the efficacy estimand, without reaching a weight plateau [48].”
InfluentialPatil, S., Jha, N., & Jha, M. K. (2026) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2026.100671 · Cited by 24
“…and future studies are needed with orally available compounds (potentially increase acceptability and access) (Rosenstock et al., 2025; Wharton et al., 2025; Wharton et al., 2023) and with longer duration of action (such as monthly injections which may improve compliance) (Jastreboff et al., 2025).”
Khan, S. S., Bhave, N. M., Blumenthal, R. S., Coresh, J., Huang, X., Joseph, J. J., Khera, A., Ho, J. E., Lloyd‐Jones, D. M., Wang, C. C. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001447 · Cited by 19
ROSENSTOCK, J., Lingvay, I., RYAN, D. H., Jastreboff, A. M., Kushner, R., ACOSTA, A., Blevins, T., Choi, M., HOLMES, F. L., Smith, T., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04476-6 · Cited by 9
“Notably, the proactive collection of GI AEs through an electronic diary (e-diary) provided more rigorous evaluations of AEs but introduced potential ascertainment bias and possibly higher reporting compared with non-solicited AE reporting 15 .”
Self-citationWeight maintenance after discontinuation of GLP-1 therapies
Moiz, A., Filion, K. B., Knäuper, B., Tsoukas, M. A., Brazeau, A.-S., Zolotarova, T., Lelièvre, A., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103992 · Cited by 7
“78,106,107 Although long-term safety data are generally reassuring, continued evaluation will be essential to support sustained use and inform clinical and policy decisions.”
The role of the incretin GIP in inflammation
Rossi, G., Bucciarelli, L. G., Cimino, V., & Fiorina, P. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02719-w · Cited by 7
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“A recent publication in the New England Journal of Medicine detailed a Phase 2 trial of Maridebart cafraglutide, also known as MariTide or AMG133 (developed by Amgen) [402].”
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
Davies, I., Turland, A., Tran, H. D., Wong, C., Cahn, O., Dunsterville, C., Sun, Y., Xiao, Y., Murphy, K. G., Bloom, S. R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70300 · Cited by 3
“11,12 While previous studies have described metabolic consequences of either GIPR agonist or antagonist treatment in isolation, 2,6,7,13,14 an in-depth side-by-side comparison of each approach of GIPR targeting has yet to be conducted.”
Advances in incretin-based drug discovery in 2025
Müller, T. D. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01219-4 · Cited by 4
“Individuals received MariTide at doses of 140 mg, 280 mg or 420 mg every month without dose escalation, 420 mg every month with either a 4-week or 12-week dose escalation, 420 mg every other month or placebo 3 .”
InfluentialZhang, H., Liu, Y., Zhang, S., Wang, Z., Zhang, X., Zhang, Y., Zhang, J., Liang, S., Li, C., Su, M., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04261-0 · Cited by 7
“GLP-1RAs used for the treatment of type 2 diabetes was gradually expanded to other diseases, such as obesity [42], non-alcoholic fatty liver disease [43], and Alzheimer’s disease [44].”
Self-citationWu, B., Falsey, J. R., Netirojjanakul, C., Herberich, B., Holder, J. R., Sham, K. K. C., Aral, J., Forsythe, N., Walker, K. W., Lu, S.-C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00032 · Cited by 4
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Ono, Y. O. I., Shinohara, K., Nakashima, H., Miyamoto, R., Hara, A., Ikeda, S., Matsumoto, S., Yoshida, D., Nakashima, R., Matsushima, S., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02632-6 · Cited by 3
“…this concept, a recent clinical study demonstrated that mar-idebart cafraglutide, a long-acting peptide – antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism, resulted in substantial weight reduction in individuals with obesity, with or without type 2 diabetes [51].”
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026) · Obesity · doi:10.1002/oby.70212 · Cited by 3
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism
Lewis, J. E., Montaner, M., Nuzzaci, D., James-Okoro, P.-P., Harada, N., Inagaki, N., Dodson, W. S., Knerr, P. J., Douros, J. D., Gribble, F. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01575-z · Cited by 6
“Both GIPR co-agonism (as in tirzepatide) and GIPR antagonism (as in MariTide, a bispecific hybrid molecule comprising two GLP-1R agonist peptides conjugated to a monoclonal anti-GIPR antagonistic antibody) are effective in treating people living with obesity 2,3,22 .”
More than a sidekick: GIP signalling and cardiovascular outcomes
Kurt, B., & Kahles, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf944 · Cited by 3
“15 The current study by Emanuelsson et al . provides important novel findings, but we have to see the outcome data if antagonism or agonism of the GIPR could improve CV prognosis in patients with obesity and established ASCVD.”
Luca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
Khachaturov, M., & Goulis, D. G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70822 · Cited by 3
Should weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 2
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Antza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Managing Obesity in Individuals with Cardiovascular Disease: Are We Missing the Obvious?
Gao, M., Kurala, T. S., & Ajjan, R. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.53 · Cited by 1
“47 Recently, a small molecule mimetic of GLP-1 receptor, orforglipron, has shown promise as a weight loss agent that improves glycaemia in early T2D.”
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk
Kang, Y. M., Harrington, J., Aroda, V. R., & McGuire, D. K. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01296-6 · Cited by 1
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Yie, J., Mou, Z., & Liu, X. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag029 · Cited by 2
Xie, J., Yang, Y., Chen, W., (45927), L. W., Weng, S., Lyu, Q., & Cao, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00722-7 · Cited by 1
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.003 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
Once-Monthly Maridebart Cafraglutide in Obesity — A Phase 2 Trial
Jastreboff, A. M., Ryan, D. H., & Pannacciulli, N. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2514331 · Cited by 1
Self-citationBeyond the Skinfolds: Diagnostic and Therapeutic Hope for the Obese and Formerly Obese
Miller, D. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.014
Collazo–Clavell, M. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2510196
The importance of science communication surrounding weight-loss drugs
Yeo, G. S. H. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00320-1
Selective amylin receptor agonism: promise beyond incretins
van Beek, A. P. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02214-7
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
Lee, H. M., Marakkalage, K. G., Kim, S. H., Lee, S., Lee, J. H., Park, H. S., & Yoo, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02161-9
“Their proven ef fi cacy has driven the development of novel obesity pharmacotherapies targeting GLP-1 receptor activity [4 – 6].”
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
Saldívar-Cerón, H. I. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94010021
“…interest in ultra-long-acting formulations capable of maintaining therapeutic potency while reducing injection burden, setting the stage for the development of once-monthly injectable agents targeting GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and related metabolic pathways [14–16].”
InfluentialRetatrutide in type 2 diabetes mellitus and obesity: an overview
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2642415
“Advances in pharmacology might allow a less frequent administration, similar to other currently available agents, but with more pronounced effects [65, 66].”
Obesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation
Costa, T. A., Harrington, J., Nelson, A. J., Pandey, A., Neeland, I. J., Lee, M. M. Y., Kang, Y. M., & McGuire, D. K. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-026-01138-1
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“Maritide was also associated with significant improvement on cardiometabolic parameters such as BP, triglycerides, and high-sensitivity C-reactive protein (hs-CRP) [76,77].”
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“The multinational MariTide phase 2 obesity trial evaluated the efficacy and safety of MariTide at doses from 140 to 420 mg with or without escalation over 52 weeks, in adults with obesity with or without diabetes [35].”
InfluentialNext-generation anti-obesity drugs: Mechanisms, molecules, and momentum
Mukheja, Y., Kondepudi, K. K., Chopra, K., & Bishnoi, M. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100701 · Cited by 1
Long, Y., Xu, Z., Zhang, N., Chen, G., Chen, W., Chen, Z., Wang, A., Liang, Z., Wang, Y., Zeng, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.21.719783
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Helsted, M. M., FONNESBECH-WULFF, C. C., Schaltz, N. L., Lund, I. W., Forman, J. L., Nielsen, C. K., Englund, A., Hartmann, B., Vilsbøll, T., Holst, J. J., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00075-6
Khan, S. S., Ndumele, C. E., Bhave, N. M., Blumenthal, R. S., Coresh, J., Huang, X., Joseph, J. J., Khera, A., Ho, J. E., Lloyd‐Jones, D. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.007 · Cited by 4
Patil, M., Piccinini, F., Johnstone, E. K. M., Casari, I., & Falasca, M. (2026) · Bioscience Reports · doi:10.1042/bsr20250114 · Cited by 1
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy
Lee, S. M., Song, H., & Kwon, Y. O.-S. (2026) · Pharmaceuticals · doi:10.3390/ph19071047
“An ultralong-acting GLP-1R agonist maridebart cafraglutide (MariTide) was tested in clinical trials as once-monthly (once every four weeks) subcutaneous injections [16,18].”
InfluentialGLP-1R and GIPR crosstalk modulates insulinotropic signaling pathways
Lindquist, P., Dijkhof, L. R. H., Drzazga, A. K., Sabatier, P., Stępniewski, T. M., Granlund, L., Lechner, M. Y., Zhong, Y., Gasbjerg, L. S., Hartmann, B., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.003
CagriSema: a novel dual-pathway approach to target obesity and its complications
Calero, I. V., Rodríguez, A., & Frühbeck, G. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.101
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
Dei, A., Aldigeri, R., Maglietta, G., Balestreri, E., Garofolo, M., Daniele, G., Penno, G., Trombetta, M., Csermely, A., Antonini, M., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02930-3
Agonists and Antagonists of the Human GIP Receptor
Kizilkaya, H. S., Gasbjerg, L. S., Holst, J. J., & Rosenkilde, M. M. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch2
Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions
Kamrul-Hasan, A. B. M., Kalra, A., Kapoor, N., Dutta, D., Mahajan, K., Maskey, R., & Raza, S. A. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70307
“Maridebart cafraglutide (MariTide), a long-acting GLP-1 RA conjugated to a GIP receptor antagonist, has shown 11.1% to 13.8% placebo-adjusted weight loss at 52 weeks with once-monthly dosing in phase 2 trials [51].”
InfluentialGlucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
“Among participants with obesity but without type 2 diabetes, AMG133 led to a mean weight loss of 20% after 52 weeks, using a dose escalation up to a 420 mg monthly dose [124].”
InfluentialMazzone, P. M., Giacoppo, D., Ammirabile, N., Mauro, M. S., Spagna, F., & Capodanno, D. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag430
The End of -mab: More than a Change in Nomenclature
Sharma, S., & Raja, Y. (2026) · doi:10.5005/aijms-11038-0027
Papastathopoulou, N. S., Neri, S., Assirelli, E., D’Amuri, A., Greco, S., Ciaffi, J., & Ursini, F. (2026) · Rheumatology Advances in Practice · doi:10.1093/rap/rkag105
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
DeCoster, M., & Narla, S. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.08.013
RetractedPharmacological management of obesity: Current landscape and emerging therapies
Atal, S., Agrawal, C., Gupta, R., & Sadasivam, B. (2026) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_37_26
“[30] It is now being evaluated in a phase 3 program called MARITIME .”
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
Jastreboff, A. M., Ard, J. D., Hall, K. D., Kaplan, L. M., Krumholz, H. M., Name, M. A. V., Ryan, D. H., & Drucker, D. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag025 · Cited by 1
Self-citationStructural Overview of GLP-1 Analogs
van der Velden, W. J. C., Andresen, A. F., & ROSENKILDE, M. M. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101037
He, Q., Shan, H., Hu, W., Xu, H. E., & Zhao, L. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01923-5
Martino, S. D., & Rosa, M. D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930768
“These outcomes prompted its advancement in to phase 3 clinical trials under the brand name MariTide (Véniant et al., 2024; Jastreboff et al., 2025).”
Obesity, incretin-based therapies, and cardiovascular disease in women
Salih, M., Sloots, Y. A. J., Hemels, M. E. W., Meems, L. M. G., Leening, M. J. G., & Ghossein‐Doha, C. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02084-0
“Dual agonist maridebart cafraglutide and triple-hormone-receptor agonist retatrutide further expand therapeutic possibilities [48, 49]; retatrutide achieved average weight loss up to around 24% after 48 weeks, compared to placebo [48].”
Effect of GLP‐1 receptor agonist on nutrient intake: A narrative review
Fujioka, K. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70172
“28 The idea that both stimulating and blocking the GIP receptor can lead to weight loss shows just how complex appetite regulation is.”
Future GLP-1 receptor co-agonists and their cardiac effects
Neumann, J., Kirchhefer, U., Hofmann, B., & Gergs, U. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05908-3
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Ismaiel, A., & Dumitrascu, D. L. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102146
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Novel Anti-Obesity Drugs: Pharmacokinetics, Pharmacodynamics, and Precision Dosing
Badawoud, A. M., Zaafar, D. K., AlRasheed, H. A., Aldossary, K. M., Alsharif, A. A., & Alsaleh, N. A. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00482-x
Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ahmad, I., Azmi, S., Albabtain, M. A., Mustafa, M., Kunnathodi, F., Riyasdeen, A., AlWhaiby, B. R., Alharbi, E. M., Arafat, A. A., & Alotaibi, H. F. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101281
Metadata
- Authors
- Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., & Pannacciulli, N.
- Affiliations
- Yale University (US)
- Pennington Biomedical Research Center (US)
- University of Louisville (US)
- Monash Health (AU)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-09-04
- Volume
- 393
- Issue
- 9
- Pages
- 843-857
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4411542117
- Cited by
- 110
- References
- 34
- Citations by year
- 2026: 89 · 2025: 21
- FWCI
- 61.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, type 2 diabetes, GLP-1 receptor agonists, GIP receptor antagonist, weight loss, dose escalation, once-monthly dosing, dose-ranging, treatment policy estimand, weight regain after weight loss, adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Receptors, Gastrointestinal Hormone, Weight Loss, Body Mass Index, Immunoconjugates, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.